Pemetrexed Pfizer 100 mg powder for concentrate for solution for infusion

DRUG2 trials

Sponsors

Summit Therapeutics Inc., Glaxosmithkline Research & Development Limited

Conditions

Lung CancerNon-Small CellPatients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment

Phase 2

A RANDOMIZED, PHASE 2, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF DOSTARLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

CompletedCTIS2023-505894-33-00

Glaxosmithkline Research & Development LimitedLung Cancer, Non-Small Cell

Start: 2020-11-25End: 2024-09-10Target: 114Updated: 2024-02-29

Phase 3

A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)

Active, not recruitingCTIS2023-504434-22-00

Summit Therapeutics Inc.Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment

Start: 2023-10-03Target: 45Updated: 2025-12-16